Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
0.00%
)
US TECH 100
23,651.61
(
-0.29%
)
Dow Jones
46,021.43
(
0.00%
)
Brent Oil
105.56
(
1.08%
)
Bitcoin
70,240.83
(
0.49%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 120592

Friday, 11/04/2011 7:17:27 AM

Friday, November 04, 2011 7:17:27 AM

Post# of 257262
VRUS/BMY add 12-week arms to study of PSI-7977 + BMS-790052, including two arms testing Incivek/Victrelis failures:

http://finance.yahoo.com/news/New-12-Week-InterferonFree-prnews-3892030583.html?x=0&.v=1

There are four news arms, all for genotype-1 patients. Two new arms in the first-line setting test PSI-7977 + BMS-790052 for 12 weeks with or without ribavirin.

Two new arms in the second-line setting following failure on Incivek or Victrelis test test PSI-7977 + BMS-790052 for 12 weeks with or without ribavirin.

PSI-7977 is a nuke from VRUS and BMS-790052 is an NS5A inhibitor from BMY.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up